CONCLUSION
HPO is a rare syndrome that could be idiopathic or secondary to inflammatory, infectious or neoplastic cause. In this case HPO was a paraneoplastic syndrome that revealed lung cancer. Clinicians should pay close attention to physical complaints in schizophrenia because this population is vulnerable to some somatic affections. Patients with schizophrenia should be screened for lung cancer as soon as risk factors are identified.
The major risk factor for lung cancer is tobacco consumption. In this population the consumption is more important and more frequent. So, they should imperatively be addressed to programs to quit smoking. For now, we have anti-tobacco strategies that are addressed to the general population. It would be more interesting and perhaps more effective to elaborate strategies adapted to patients with schizophrenia.
1. Martínez-Lavín M. Hypertrophic osteoarthropathy. Best Pract Res Clin Rheumatol. 1 juin 2020;34(3):101507.
2. Bonnot O, Anderson GM, Cohen D, Willer JC, Tordjman S. Are patients with schizophrenia insensitive to pain? A reconsideration of the question. Clin J Pain. avr 2009;25(3):244‑52.
3. Chakraborty RK, Sharma S. Secondary Hypertrophic Osteoarthropathy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 [cité 27 juin 2021]. Disponible sur: http://www.ncbi.nlm.nih.gov/books/NBK513342/
4. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 2-1997. A 38-year-old man with digital clubbing, low-grade fever, and a murmur. N Engl J Med. 16 janv 1997;336(3):205‑10.
5. Catts VS, Catts SV, O’Toole BI, Frost ADJ. Cancer incidence in patients with schizophrenia and their first-degree relatives - a meta-analysis. Acta Psychiatr Scand. mai 2008;117(5):323‑36.
6. Lichtermann D, Ekelund J, Pukkala E, Tanskanen A, Lönnqvist J. Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen Psychiatry. juin 2001;58(6):573‑8.
7. Bradford DW, Goulet J, Hunt M, Cunningham NC, Hoff R. A Cohort Study of Mortality in Individuals With and Without Schizophrenia After Diagnosis of Lung Cancer. J Clin Psychiatry. déc 2016;77(12):e1626‑30.
8. Fujiwara M, Inagaki M, Nakaya N, Fujimori M, Higuchi Y, Hayashibara C, et al. Cancer screening participation in schizophrenic outpatients and the influence of their functional disability on the screening rate: A cross-sectional study in Japan. Psychiatry Clin Neurosci. déc 2017;71(12):813‑25.
9. Warren GW, Cummings KM. Tobacco and lung cancer: risks, trends, and outcomes in patients with cancer. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet. 2013;359‑64.
10. Sagud M, Mihaljevic Peles A, Pivac N. Smoking in schizophrenia: recent findings about an old problem. Curr Opin Psychiatry. sept 2019;32(5):402‑8.
11. Zuber V, Jönsson EG, Frei O, Witoelar A, Thompson WK, Schork AJ, et al. Identification of shared genetic variants between schizophrenia and lung cancer. Sci Rep. 12 janv 2018;8(1):674.
12. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 28 févr 2013;(2):CD007253.
13. Pearsall R, Smith DJ, Geddes JR. Pharmacological and behavioural interventions to promote smoking cessation in adults with schizophrenia and bipolar disorders: a systematic review and meta-analysis of randomised trials. BMJ Open. 28 nov 2019;9(11):e027389.